SCHEDULE: Frazier Life Sciences Divests Entire Elevation Oncology Stake

Frazier Life Sciences and its affiliates have reported a complete divestment of their beneficial ownership in Elevation Oncology, Inc., reducing their stake to 0.0%.

Summary

• Frazier Life Sciences Public Fund, L.P., along with several affiliated entities and individuals, filed an Amendment No. 2 to Schedule 13G for Elevation Oncology, Inc.
• The filing indicates that as of July 23, 2025, the reporting persons collectively hold 0.0% beneficial ownership of Elevation Oncology, Inc.'s common stock.
• This represents a complete divestment or reduction below the reporting threshold by a significant institutional investor group.
• The common stock of Elevation Oncology, Inc. has a par value of $0.0001 per share and CUSIP number 28623U101.
• The principal executive offices of Elevation Oncology, Inc. are located at 101 Federal Street, Suite 1900, Boston, MA, 02110.

Sentiment

Score: 2

Explanation: The complete divestment by a major institutional investor is a strong negative signal, indicating a lack of confidence in the company's prospects.

Negatives

• A significant institutional investor group, Frazier Life Sciences and its affiliates, has reduced its beneficial ownership in Elevation Oncology, Inc. to 0.0%.
• This complete divestment by a major investor could signal a loss of confidence in the company's future prospects or a strategic shift away from the investment.

Risks

• The complete divestment by a major institutional investor like Frazier Life Sciences may lead to negative market sentiment and increased selling pressure on Elevation Oncology, Inc.'s stock.
• Such a move could be interpreted by other investors as a lack of belief in the company's long-term strategy, clinical pipeline, or financial stability.

Future Outlook

The filing is a Schedule 13G amendment reporting a change in beneficial ownership and does not contain forward-looking statements or guidance from the issuer.

Industry Context

The divestment by Frazier Life Sciences, a prominent life sciences investor, could be a reflection of their portfolio rebalancing or a specific assessment of Elevation Oncology's position within the competitive oncology biotechnology landscape. Such moves by specialized funds are closely watched for signals regarding sector-specific opportunities or challenges.

Stakeholder Impact

• Shareholders: Existing shareholders may experience negative sentiment and potential share price depreciation due to the significant divestment by a major investor.
• Potential Investors: New investors may be deterred by the exit of a prominent life sciences fund, leading to reduced demand for the stock.

Key Dates

Recommendation

The complete divestment by Frazier Life Sciences, a sophisticated and specialized life sciences investor, signals a profound lack of confidence in Elevation Oncology, Inc. This action suggests that the fund no longer sees value or growth potential in the company, or perceives significant risks. Such a move by a major institutional holder is a strong negative indicator and warrants a 'strong sell' recommendation, as it is likely to trigger further downward pressure on the stock price and erode investor confidence.

Keywords

Elevation Oncology, Frazier Life Sciences, Schedule 13G, Beneficial Ownership, Divestment, Institutional Investor, Common Stock, Biotechnology, Oncology